Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus placebo as adjuvant therapy after curative resection or ablation in high-risk hepatocellular carcinoma
CTR20180927Phase 3Suspended
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Jan 2019; status: suspended.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20180927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180927.